BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Amira Pharmaceuticals, Inc. 

9535 Waples Street
Suite 100
San Diego  California  92121  U.S.A.
Phone: 858-228-4650 Fax: 858-558-8445


Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a privately held small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease. The company combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.

 Key Statistics

Ownership: Private

Web Site: Amira Pharmaceuticals, Inc.
Employees: 50

Start Up

 Company News
Panmira Pharmaceuticals, LLC. and FLAP LLC Spun Out of Amira Pharmaceuticals, Inc. 9/8/2011 3:00:17 PM
Bristol-Myers Squibb Company (BMY) Completes Acquisition of Amira Pharmaceuticals, Inc. 9/8/2011 10:51:38 AM
Bristol-Myers Squibb Company (BMY) to Pay Up to $475 Million for Amira Pharmaceuticals, Inc., Scoops Up Lung Drug 7/22/2011 6:32:43 AM
Amira Pharmaceuticals, Inc. Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist 5/2/2011 9:17:44 AM
Amira Pharmaceuticals, Inc. Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis 4/19/2011 7:32:48 AM
Findings Published in Journal of Pharmacology and Experimental Therapeutics Demonstrate Potential for Amira Pharmaceuticals, Inc.'s LPA1 Receptor Antagonist as an Anti-Fibrotic Agent 1/5/2011 9:13:32 AM
Amira Pharmaceuticals, Inc. Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 12/15/2010 11:12:11 AM
Amira Pharmaceuticals, Inc. to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010 12/14/2010 10:51:02 AM
Amira Pharmaceuticals, Inc. Cuts Half of Staff, Scientific Founders Exit as Company Seeks to Conserve Cash 11/24/2010 7:04:47 AM
Amira Pharmaceuticals, Inc. Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 10/28/2010 10:42:30 AM